Drug or treatment

Tremelimumab clinical trials

• 26Clinical trials
• 20Countries

Newest trials

All recruiting trials (26)

• STRIDE combination in advanced liver cancer: a first-line look at tremelimumab plus durvalumab

  This study tests tremelimumab plus durvalumab as a first-line treatment in adults with advanced or unresectable hepatocellular carcinoma to see how it affects liver health, quality of life, effectiveness, and safety.

  Recruiting at 17 sites AstraZeneca · Ancona and 23 other locations · NCT07607769

• RBS2418 with tremelimumab and durvalumab for advanced unresectable liver cancer

  This trial will test whether adding RBS2418 to tremelimumab plus durvalumab helps adults with advanced, unresectable hepatocellular carcinoma.

  Recruiting at 4 sites Phase 2 Riboscience, LLC. · Baltimore, Maryland and 3 other locations · NCT07175441

• Celecoxib with durvalumab and tremelimumab for advanced liver cancer

  This phase II trial tests whether adding the oral drug celecoxib to the immunotherapy drugs durvalumab and tremelimumab helps people with advanced or metastatic liver cancer.

  Recruiting at 3 sites Phase 2 Emory University · Atlanta, Georgia and 3 other locations · NCT07174570

• Y-90 internal liver radiation followed by tremelimumab and durvalumab for liver cancer with portal vein thrombosis

  This will test whether Y-90 selective internal radiation (SIRT) followed by tremelimumab and durvalumab helps people with non-resectable hepatocellular carcinoma that involves the portal vein.

  Recruiting Phase 2 Center Eugene Marquis · Grenoble and 5 other locations · NCT07122089

• Radiation therapy followed by immune therapy and surgery for hepatocellular carcinoma

  This trial tests whether adding durvalumab and tremelimumab to radiation therapy before surgery helps people with resectable liver cancer.

  Recruiting Phase 3 Hamilton Health Sciences Corporation · Hamilton, Ontario and 1 other locations · NCT07027436

• Photon radiotherapy plus tremelimumab and durvalumab for intermediate or advanced hepatocellular carcinoma

  This trial tests whether adding targeted photon radiotherapy to tremelimumab plus durvalumab helps people with unresectable intermediate or advanced (BCLC B or C) hepatocellular carcinoma respond better to treatment.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06999707

• Proton radiation with tremelimumab and durvalumab for BCLC stage B/C hepatocellular carcinoma

  This will test whether adding precise proton radiation to tremelimumab plus durvalumab helps people with unresectable BCLC stage B or C hepatocellular carcinoma.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06999694

• Rilvegostomig plus bevacizumab, with or without tremelimumab, versus atezolizumab plus bevacizumab for advanced liver cancer

  This trial tests whether rilvegostomig combined with bevacizumab, with or without tremelimumab, works better than atezolizumab plus bevacizumab as first-line treatment for people with advanced hepatocellular carcinoma who are not candidates for curative or locoregional therapy.

  Recruiting at 189 sites Phase 3 AstraZeneca · Phoenix, Arizona and 225 other locations · NCT06921785

• Evaluating a combination treatment for advanced liver cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it helps patients live longer and feel better.

  Recruiting Phase 1/2 Seoul National University Hospital · Seoul · NCT06911255

• Durvalumab plus tremelimumab with or without liver-directed GEMOX chemotherapy for hepatocellular carcinoma

  This trial tests whether adding hepatic arterial infusion chemotherapy (GEMOX) to the immunotherapy combination durvalumab plus tremelimumab helps people with hepatocellular carcinoma who have a high tumor burden in the liver.

  Recruiting at 5 sites Phase 2/3 Unicancer · Bordeaux and 10 other locations · NCT06904170

• Durvalumab + Tremelimumab with or without Lenvatinib for unresectable liver cancer

  This trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) helps people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting at 13 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 12 other locations · NCT06880523

• Biomarkers to predict outcomes in liver cancer treated with tremelimumab plus durvalumab

  This study will test whether blood biomarkers can predict how adults with unresectable or metastatic hepatocellular carcinoma respond to tremelimumab plus durvalumab (STRIDE regimen).

  Recruiting at 10 sites Centre Hospitalier Universitaire de Besancon · Besançon and 9 other locations · NCT06796114

• Combining Zanzalintinib with Immunotherapy for Liver Cancer

  This study is testing a new combination of a cancer drug and immunotherapy to see if it can help people with advanced liver cancer feel better and fight their disease.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania and 2 other locations · NCT06698250

• Evaluating immunotherapy for colorectal and endometrial cancer

  This study is testing a new immunotherapy treatment for people with colorectal or endometrial cancer to see if a combination of two drugs can help them better than just one.

  Recruiting Phase 2 Vall d'Hebron Institute of Oncology · Barcelona · NCT06680739

• Targeting driver oncogenes in biliary tract cancer with a personalized peptide vaccine plus durvalumab and tremelimumab

  This trial will test whether a personalized mutant peptide vaccine given with durvalumab and tremelimumab is safe and stimulates an immune response in people with advanced biliary tract cancer after first-line chemotherapy and anti–PD-(L)1 therapy.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06564623

• Treatment for advanced liver cancer with specific cirrhosis

  This study is testing a new combination treatment for advanced liver cancer in patients with specific cirrhosis to see if it can help them better than current options, especially focusing on those from underserved communities.

  Recruiting Phase 2 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT06526104

• Examining the effectiveness of a treatment combination in patients with advanced lung cancer

  This study is testing a new treatment combination for patients with advanced lung cancer to see how well it works based on their specific genetic markers.

  Recruiting at 27 sites AstraZeneca · Bad Homburg and 29 other locations · NCT06494540

• Neoadjuvant chemotherapy and immunotherapy for advanced cholangiocarcinoma

  This study is testing a combination of chemotherapy and immunotherapy before surgery to see if it can help people with advanced cholangiocarcinoma have fewer cancer recurrences within a year after their operation.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples, Italia and 5 other locations · NCT06341764

• Combining radioembolization with immunotherapy for advanced bile duct cancer

  This study is testing a new treatment that combines a special type of radiation therapy with immunotherapy drugs to see if it can help patients with advanced bile duct cancer who can't have surgery.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06058663

• Combination of immunotherapy and chemotherapy for mesothelioma treatment

  This study is testing whether combining two immunotherapy drugs with chemotherapy can help people with a type of lung cancer called mesothelioma live longer without their cancer coming back.

  Recruiting Phase 1/2 Baylor College of Medicine · Durham, North Carolina and 1 other locations · NCT05932199

• Triple treatment for advanced liver cancer patients

  This study is testing two different ways to treat advanced liver cancer to see which one works better for patients who can't have surgery.

  Recruiting at 3 sites Phase 2 Ludwig-Maximilians - University of Munich · Munich and 2 other locations · NCT05844046

• Combination treatment of Durvalumab and Tremelimumab for liver cancer before surgery

  This study is testing whether a combination of two immune treatments, Durvalumab and Tremelimumab, can help people with early to intermediate liver cancer do better before surgery.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario and 2 other locations · NCT05440864

• Combining durvalumab and tremelimumab with chemotherapy for HIV-infected lung cancer patients

  This study is testing if a combination of two immune treatments with chemotherapy can help people with stage IV lung cancer who are also living with HIV.

  Recruiting at 4 sites Phase 2 Georgetown University · Washington D.C., District of Columbia and 3 other locations · NCT04499053

• Radiation therapy followed by immune therapy for advanced liver cancer

  This study is testing whether a combination of radiation therapy and immune treatments can help people with advanced liver cancer that hasn't improved after other treatments.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT04430452

• Treatment with durvalumab for cancer patients who had side effects from previous therapies

  This study is testing if the immunotherapy drug durvalumab, combined with prednisone, can help cancer patients who had side effects from previous treatments while also seeing if it can slow down their cancer.

  Recruiting at 10 sites Phase 2 Canadian Cancer Trials Group · Edmonton, Alberta and 10 other locations · NCT03847649

• Combining a personalized vaccine with chemotherapy and immunotherapy for metastatic triple-negative breast cancer

  This study is testing if adding a personalized vaccine to chemotherapy and immunotherapy can help people with metastatic triple-negative breast cancer feel better and improve their treatment outcomes.

  Recruiting at 24 sites Phase 2 National Cancer Institute (NCI) · Orange, California and 29 other locations · NCT03606967

Quick answers

How many clinical trials of Tremelimumab are recruiting right now?

26, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 20 countries. The most sites are in United States (11 trials), Canada (5 trials), Italy (4 trials), France (4 trials), Spain (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 16, Phase 1/2: 2, Phase 1: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →